117 related articles for article (PubMed ID: 17638612)
41. Tumours.
Falini A; Romano A; Bozzao A
Neurol Sci; 2008 Oct; 29 Suppl 3():327-32. PubMed ID: 18941724
[TBL] [Abstract][Full Text] [Related]
42. Potential impact of molecular imaging in oncology.
Klutmann S; Clausen M
Anticancer Res; 2005; 25(3A):1827-8. PubMed ID: 16033107
[TBL] [Abstract][Full Text] [Related]
43. Imaging can be much more than pretty pictures.
Wolf W
Pharm Res; 1995 Dec; 12(12):1821-2. PubMed ID: 8786952
[No Abstract] [Full Text] [Related]
44. Advanced imaging of colorectal cancer: From anatomy to molecular imaging.
García-Figueiras R; Baleato-González S; Padhani AR; Marhuenda A; Luna A; Alcalá L; Carballo-Castro A; Álvarez-Castro A
Insights Imaging; 2016 Jun; 7(3):285-309. PubMed ID: 27136925
[TBL] [Abstract][Full Text] [Related]
45. Advanced MRI in neuro-oncology: can we proceed without inclusion of energy metabolism?
Stadlbauer A; Buchfelder M; Dörfler A; Oberndorfer S
Oncotarget; 2019 Jun; 10(40):3994-3995. PubMed ID: 31258841
[No Abstract] [Full Text] [Related]
46. Hybrid PET/MRI in Cerebral Glioma: Current Status and Perspectives.
Langen KJ; Galldiks N; Mauler J; Kocher M; Filß CP; Stoffels G; Régio Brambilla C; Stegmayr C; Willuweit A; Worthoff WA; Shah NJ; Lerche C; Mottaghy FM; Lohmann P
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509252
[TBL] [Abstract][Full Text] [Related]
47. Machine learning in neuroimaging: from research to clinical practice.
Nenning KH; Langs G
Radiologie (Heidelb); 2022 Dec; 62(Suppl 1):1-10. PubMed ID: 36044070
[TBL] [Abstract][Full Text] [Related]
48. Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology.
Kasten BB; Udayakumar N; Leavenworth JW; Wu AM; Lapi SE; McConathy JE; Sorace AG; Bag AK; Markert JM; Warram JM
Theranostics; 2019; 9(17):5085-5104. PubMed ID: 31410203
[TBL] [Abstract][Full Text] [Related]
49. Metabolism of Stem and Progenitor Cells: Proper Methods to Answer Specific Questions.
Martano G; Borroni EM; Lopci E; Cattaneo MG; Mattioli M; Bachi A; Decimo I; Bifari F
Front Mol Neurosci; 2019; 12():151. PubMed ID: 31249511
[TBL] [Abstract][Full Text] [Related]
50. Comparison of dual-time point 18F-FDG PET/CT tumor-to-background ratio, intraoperative 5-aminolevulinic acid fluorescence scale, and Ki-67 index in high-grade glioma.
Kim YI; Cho KG; Jang SJ
Medicine (Baltimore); 2019 Feb; 98(8):e14397. PubMed ID: 30813140
[TBL] [Abstract][Full Text] [Related]
51. Region-by-region analysis of PET, MRI, and histology in en bloc-resected oligodendrogliomas reveals intra-tumoral heterogeneity.
Roodakker KR; Alhuseinalkhudhur A; Al-Jaff M; Georganaki M; Zetterling M; Berntsson SG; Danfors T; Strand R; Edqvist PH; Dimberg A; Larsson EM; Smits A
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):569-579. PubMed ID: 30109401
[TBL] [Abstract][Full Text] [Related]
52. Recurrence patterns after maximal surgical resection and postoperative radiotherapy in anaplastic gliomas according to the new 2016 WHO classification.
Im JH; Hong JB; Kim SH; Choi J; Chang JH; Cho J; Suh CO
Sci Rep; 2018 Jan; 8(1):777. PubMed ID: 29335518
[TBL] [Abstract][Full Text] [Related]
53. Comparison of
Verger A; Filss CP; Lohmann P; Stoffels G; Sabel M; Wittsack HJ; Kops ER; Galldiks N; Fink GR; Shah NJ; Langen KJ
Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2257-2265. PubMed ID: 28831534
[TBL] [Abstract][Full Text] [Related]
54. Amino acid PET and MR perfusion imaging in brain tumours.
Filss CP; Cicone F; Shah NJ; Galldiks N; Langen KJ
Clin Transl Imaging; 2017; 5(3):209-223. PubMed ID: 28680873
[TBL] [Abstract][Full Text] [Related]
55. Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents.
Serkova NJ; Eckhardt SG
Front Oncol; 2016; 6():152. PubMed ID: 27471678
[TBL] [Abstract][Full Text] [Related]
56. Usefulness of positron emission tomographic studies for gliomas.
Miyake K; Ogawa D; Okada M; Hatakeyama T; Tamiya T
Neurol Med Chir (Tokyo); 2016 Jul; 56(7):396-408. PubMed ID: 27250577
[TBL] [Abstract][Full Text] [Related]
57. ¹⁸F-Fluorocholine PET/CT as a complementary tool in the follow-up of low-grade glioma: diagnostic accuracy and clinical utility.
Gómez-Río M; Testart Dardel N; Santiago Chinchilla A; Rodríguez-Fernández A; Olivares Granados G; Luque Caro R; Zurita Herrera M; Chamorro Santos CE; Lardelli-Claret P; Llamas-Elvira JM
Eur J Nucl Med Mol Imaging; 2015 May; 42(6):886-95. PubMed ID: 25673054
[TBL] [Abstract][Full Text] [Related]
58. Imaging biomarkers in primary brain tumours.
Lopci E; Franzese C; Grimaldi M; Zucali PA; Navarria P; Simonelli M; Bello L; Scorsetti M; Chiti A
Eur J Nucl Med Mol Imaging; 2015 Apr; 42(4):597-612. PubMed ID: 25520293
[TBL] [Abstract][Full Text] [Related]
59. Discrimination and anatomical mapping of PET-positive lesions: comparison of CT attenuation-corrected PET images with coregistered MR and CT images in the abdomen.
Kuhn FP; Crook DW; Mader CE; Appenzeller P; von Schulthess GK; Schmid DT
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(1):44-51. PubMed ID: 22955547
[TBL] [Abstract][Full Text] [Related]
60. Accurate differentiation of recurrent gliomas from radiation injury by kinetic analysis of α-11C-methyl-L-tryptophan PET.
Alkonyi B; Barger GR; Mittal S; Muzik O; Chugani DC; Bahl G; Robinette NL; Kupsky WJ; Chakraborty PK; Juhász C
J Nucl Med; 2012 Jul; 53(7):1058-64. PubMed ID: 22653792
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
